Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Oncology Drugs Market was valued at USD 210.00 billion in 2024 and is projected to grow to USD 225.54 billion in 2025, with a CAGR of 7.92%, reaching USD 386.41 billion by 2032.
An authoritative orientation to the oncology drugs environment outlining scientific momentum, stakeholder pressures, regulatory complexity, and strategic implications for leaders
The oncology drugs landscape sits at an inflection point where scientific advances, regulatory recalibration, and shifting payer dynamics converge to reshape how therapies are developed, delivered, and reimbursed. Over recent years, incremental improvements in survival and quality of life have been supplanted by transformative modalities that target disease biology with unprecedented precision. As a result, stakeholders from clinical investigators to commercial teams confront a more complex set of choices about patient selection, biomarker validation, and value demonstration. This introduction frames the essential contextual forces that will influence near-term program prioritization and long-term portfolio architecture.
Clinicians increasingly demand evidence that goes beyond traditional endpoints to capture durable responses and real-world performance, while payers and health systems insist on predictable outcomes and budget impact mitigation. Concurrently, manufacturing and supply chain considerations for biologics and advanced therapies demand capital and operational sophistication. This confluence compels industry leaders to align translational science with commercial feasibility, and to adopt agile strategies that accommodate rapid regulatory shifts and evolving standard-of-care definitions. The subsequent sections of this summary unpack these dynamics, spotlighting where investment, collaboration, and strategic agility will deliver the greatest competitive advantage.
A forward-looking overview of the transformative shifts reshaping oncology drug development, commercialization, and delivery across science, data, and healthcare models
The oncology treatment paradigm has shifted from broadly cytotoxic approaches toward precision-enabled and immune-modulating strategies, which has recalibrated R&D priorities and commercial pathways. Advances such as engineered cellular therapies and selective small molecule inhibitors now compete alongside optimized chemotherapy backbones, compelling sponsors to rethink trial design, combination strategies, and biomarker-driven enrollment. These shifts have accelerated adaptive development models, risk-sharing agreements with payers, and a renewed emphasis on translational science to de-risk late-phase programs.
Concurrently, the industry has witnessed a move toward decentralized care delivery and digital health integration that expand trial access and patient monitoring capabilities. These transformations reduce time-to-evidence for safety and efficacy while raising the bar for evidence of long-term benefit. As a result, companies that integrate translational biomarkers, real-world evidence generation, and value-based contracting into early development are better positioned to secure reimbursement and sustain premium pricing. Looking ahead, the interplay of biology, data, and new care models will continue to upend legacy commercialization playbooks and create differentiated opportunities for stakeholders who can execute cross-functional strategies effectively.
A practical analysis of how the United States tariff changes implemented in 2025 reshaped supply chain strategy, sourcing choices, and commercial negotiations in oncology
Policy changes affecting import duties and cross-border tariffs have introduced a new layer of commercial consideration for global pharmaceutical supply chains and procurement strategies. The United States tariff adjustments implemented in 2025 have broadened the scope of landed costs for active pharmaceutical ingredients, finished dosage forms, and certain biologics components, prompting manufacturers to reassess manufacturing footprints and sourcing decisions. In response, supply chain leaders have prioritized nearshoring, dual-sourcing strategies, and contractual protections to preserve continuity and manage unit cost volatility.
These tariff developments have also influenced payer negotiations and hospital procurement behavior, as institutions weigh cost pressures against clinical necessity. Manufacturers have therefore accelerated efforts to demonstrate total cost of care benefits, including reductions in downstream resource utilization and improved patient throughput, to justify therapy selection. Moreover, some sponsors have pursued localized fill-and-finish capabilities or partnership models to mitigate tariff exposure while maintaining access to critical markets. Altogether, the cumulative impact of the 2025 tariff environment has reinforced the need for integrated commercial, manufacturing, and policy-savvy capabilities to sustain access and financial viability.
Comprehensive segmentation insights integrating drug class, administration routes, molecule typologies, indication substructures, care settings, and distribution channels to inform strategy
Segment insights reveal differentiated drivers across therapeutic classes, routes, molecular constructs, indications, end users, and distribution pathways that together define opportunity and execution risk. Based on drug class, chemotherapy agents remain relevant where cytotoxic backbones are standard, with alkylating agents and antimetabolites continuing to play a role in combinatorial regimens; hormonal therapy agents persist as critical options for hormone-driven malignancies; immunotherapy agents, including CAR T-cell therapies and checkpoint inhibitors, are reshaping durable response expectations with checkpoint inhibitors subdivided into CTLA-4 and PD-1/PD-L1 inhibitors; and targeted therapy agents, encompassing monoclonal antibodies and small molecule inhibitors, now demand precision patient selection with monoclonal antibodies studied across chimeric and humanized formats while small molecule inhibitors focus on cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors. This class-level segmentation underscores the need for tailored clinical development and commercial narratives.
When considering route of administration, injectable and oral modalities present distinct adherence, distribution, and administration challenges, with injectable forms requiring intramuscular, intravenous, or subcutaneous pathways that influence hospital and clinic workflows. Based on molecule type, biologics versus small molecules determine manufacturing complexity and regulatory pathways, where biologics include monoclonal antibodies and vaccines that carry cold-chain and scale considerations. Across indications such as blood cancer, breast, colorectal, lung, and prostate cancers, sub-segmentation in hematologic malignancies-leukemia and lymphoma-further refines strategic focus with leukemia divided into acute myeloid leukemia and chronic lymphocytic leukemia and lymphoma differentiated into Hodgkin and non-Hodgkin categories, each with unique clinical endpoints and care models. Finally, end users-hospitals, research institutes, and specialty clinics-and distribution channels-hospital pharmacies, online pharmacies, and retail pharmacies-shape access, reimbursement interactions, and provider engagement strategies. Taken together, this layered segmentation emphasizes that commercialization success requires synchronized clinical, medical affairs, and distribution planning tailored to each segment’s operational realities.
In-depth regional insights highlighting how distinct regulatory, reimbursement, and healthcare infrastructure dynamics across major global regions influence oncology therapy adoption
Regional dynamics vary substantially, influencing regulatory expectations, pricing frameworks, clinical trial landscapes, and treatment adoption curves. In the Americas, innovation hubs and large payer systems coexist with diverse regulatory pathways that incentivize rapid uptake of high-evidence therapies in specialty oncology centers while cost-containment pressures shape formulary negotiations and contracting sophistication. Across Europe, Middle East & Africa, heterogeneous health systems and reimbursement models require tailored value dossiers and country-specific access plans, with many national authorities emphasizing comparative effectiveness and budget impact analysis to guide adoption. In Asia-Pacific, dynamic growth in clinical trial capacity, rapid modernization of healthcare infrastructure, and evolving regulatory harmonization support accelerated introduction of novel agents, but market entry strategies must carefully account for localized pricing expectations and manufacturing localization opportunities.
Transitionally, these regional patterns suggest that companies should adopt differentiated market entry playbooks that align evidence generation, pricing strategy, and local partnerships with regional system characteristics. Effective regional planning balances global development efficiencies with local adaptation to ensure therapies achieve sustainable uptake and patient access across diverse health system architectures.
A granular assessment of competitive dynamics showing how established players, biotech innovators, and specialized service partners align capabilities to capture value in oncology therapeutics
Competitive positioning reflects a mix of established pharmas, emergent biotechnology innovators, and specialized contract developers that focus on niche modalities. Established companies leverage broad portfolios, deep payer relationships, and global commercial infrastructure to optimize launch sequencing and life-cycle management, while newer biotechnology firms concentrate on differentiated mechanisms of action, biomarker-driven indications, and strategic collaborations to accelerate clinical development. Contract development and manufacturing organizations, diagnostics partners, and specialized clinical operations providers play increasingly central roles in enabling scalable manufacturing and robust evidence generation.
Investor and partner activity continues to favor programs that combine strong translational rationale with feasible manufacturing and clear payer value propositions. Companies demonstrating the ability to integrate companion diagnostics, generate real-world evidence, and execute risk-sharing arrangements with payers gain access advantages. Moreover, cross-sector alliances-linking biotechs with specialty pharmacies, clinical networks, and technology providers-are becoming commonplace to ensure seamless patient identification, therapy delivery, and outcomes tracking. Taken together, these competitive dynamics favor organizations that align scientific differentiation with pragmatic commercialization and delivery capabilities.
Practical and prioritized recommendations for industry leaders to integrate translational science, manufacturing resilience, market access, and data strategies for durable commercial success
Industry leaders must prioritize integrated strategies that connect scientific differentiation to practical delivery, reimbursement, and scale. First, align translational development with value demonstration by embedding health economics and outcomes research early in clinical programs to produce robust evidence that resonates with payers and health systems. Second, invest in manufacturing flexibility and supply chain redundancy to mitigate tariff exposure and geopolitical risk while enabling rapid scale-up for biologics and cell therapies. Third, cultivate strategic partnerships across diagnostics, specialty pharmacies, and clinical networks to ensure efficient patient identification and adherence support, thereby maximizing real-world outcomes.
Additionally, adopt data-forward commercialization models that combine real-world evidence with adaptive trial designs and post-launch evidence generation to sustain reimbursement and justify premium pricing. Strengthen market access capabilities by preparing differentiated value dossiers at the country level and exploring outcomes-based contracting where appropriate. Finally, build cross-functional governance that aligns R&D, commercial, regulatory, and manufacturing decision-making to reduce time-to-launch and increase the probability of sustainable uptake. These actions, taken together, will enable organizations to convert scientific advances into durable commercial success while managing operational and policy headwinds.
A transparent and robust research methodology combining qualitative expert insights with secondary evidence and scenario analysis to underpin actionable conclusions for stakeholders
The research underpinning this analysis synthesizes primary and secondary inputs to ensure balanced, rigorous conclusions. Primary research incorporated interviews with clinical investigators, payer representatives, manufacturing and supply chain experts, and commercial leaders to validate strategic assumptions and operational constraints. Secondary research included peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public filings to triangulate factual details about therapeutic mechanisms, safety profiles, and clinical pathway evolution. These combined sources enabled a nuanced view of both technical feasibility and commercial applicability.
Methodologically, qualitative insights were mapped against observable operational trends to identify inflection points and risk factors. Where appropriate, scenario analysis was used to explore the implications of policy shifts and supply chain disruptions. The approach prioritized transparency in source attribution, methodological rigor in cross-validation, and practical framing for decision-makers. Limitations were acknowledged, including inherent uncertainty in future regulatory and reimbursement dynamics and variability across regional healthcare systems, which the methodology sought to mitigate through diverse stakeholder engagement and iterative validation.
A concise conclusion synthesizing how scientific advances, policy pressures, and strategic execution combine to determine oncology therapy adoption and long-term value
This executive summary synthesizes the critical dynamics that will shape oncology therapeutics in the near term: scientific innovation continues to expand therapeutic options, policy shifts and tariff changes compel operational adaptability, and fragmented regional systems demand customized access strategies. Strategic success will hinge on the ability to integrate translational science with manufacturing agility, evidence generation, and market access planning. Companies that operationalize cross-functional alignment, invest in localized manufacturing and supply resiliency, and build compelling value stories grounded in real-world outcomes will secure sustainable adoption.
In closing, the landscape rewards organizations that pair scientific differentiation with pragmatic delivery capabilities and proactive payer engagement. By doing so, stakeholders can translate clinical promise into measurable patient benefit and enduring commercial value, even as external pressures and rapid innovation continue to redefine what constitutes effective oncology care.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative orientation to the oncology drugs environment outlining scientific momentum, stakeholder pressures, regulatory complexity, and strategic implications for leaders
The oncology drugs landscape sits at an inflection point where scientific advances, regulatory recalibration, and shifting payer dynamics converge to reshape how therapies are developed, delivered, and reimbursed. Over recent years, incremental improvements in survival and quality of life have been supplanted by transformative modalities that target disease biology with unprecedented precision. As a result, stakeholders from clinical investigators to commercial teams confront a more complex set of choices about patient selection, biomarker validation, and value demonstration. This introduction frames the essential contextual forces that will influence near-term program prioritization and long-term portfolio architecture.
Clinicians increasingly demand evidence that goes beyond traditional endpoints to capture durable responses and real-world performance, while payers and health systems insist on predictable outcomes and budget impact mitigation. Concurrently, manufacturing and supply chain considerations for biologics and advanced therapies demand capital and operational sophistication. This confluence compels industry leaders to align translational science with commercial feasibility, and to adopt agile strategies that accommodate rapid regulatory shifts and evolving standard-of-care definitions. The subsequent sections of this summary unpack these dynamics, spotlighting where investment, collaboration, and strategic agility will deliver the greatest competitive advantage.
A forward-looking overview of the transformative shifts reshaping oncology drug development, commercialization, and delivery across science, data, and healthcare models
The oncology treatment paradigm has shifted from broadly cytotoxic approaches toward precision-enabled and immune-modulating strategies, which has recalibrated R&D priorities and commercial pathways. Advances such as engineered cellular therapies and selective small molecule inhibitors now compete alongside optimized chemotherapy backbones, compelling sponsors to rethink trial design, combination strategies, and biomarker-driven enrollment. These shifts have accelerated adaptive development models, risk-sharing agreements with payers, and a renewed emphasis on translational science to de-risk late-phase programs.
Concurrently, the industry has witnessed a move toward decentralized care delivery and digital health integration that expand trial access and patient monitoring capabilities. These transformations reduce time-to-evidence for safety and efficacy while raising the bar for evidence of long-term benefit. As a result, companies that integrate translational biomarkers, real-world evidence generation, and value-based contracting into early development are better positioned to secure reimbursement and sustain premium pricing. Looking ahead, the interplay of biology, data, and new care models will continue to upend legacy commercialization playbooks and create differentiated opportunities for stakeholders who can execute cross-functional strategies effectively.
A practical analysis of how the United States tariff changes implemented in 2025 reshaped supply chain strategy, sourcing choices, and commercial negotiations in oncology
Policy changes affecting import duties and cross-border tariffs have introduced a new layer of commercial consideration for global pharmaceutical supply chains and procurement strategies. The United States tariff adjustments implemented in 2025 have broadened the scope of landed costs for active pharmaceutical ingredients, finished dosage forms, and certain biologics components, prompting manufacturers to reassess manufacturing footprints and sourcing decisions. In response, supply chain leaders have prioritized nearshoring, dual-sourcing strategies, and contractual protections to preserve continuity and manage unit cost volatility.
These tariff developments have also influenced payer negotiations and hospital procurement behavior, as institutions weigh cost pressures against clinical necessity. Manufacturers have therefore accelerated efforts to demonstrate total cost of care benefits, including reductions in downstream resource utilization and improved patient throughput, to justify therapy selection. Moreover, some sponsors have pursued localized fill-and-finish capabilities or partnership models to mitigate tariff exposure while maintaining access to critical markets. Altogether, the cumulative impact of the 2025 tariff environment has reinforced the need for integrated commercial, manufacturing, and policy-savvy capabilities to sustain access and financial viability.
Comprehensive segmentation insights integrating drug class, administration routes, molecule typologies, indication substructures, care settings, and distribution channels to inform strategy
Segment insights reveal differentiated drivers across therapeutic classes, routes, molecular constructs, indications, end users, and distribution pathways that together define opportunity and execution risk. Based on drug class, chemotherapy agents remain relevant where cytotoxic backbones are standard, with alkylating agents and antimetabolites continuing to play a role in combinatorial regimens; hormonal therapy agents persist as critical options for hormone-driven malignancies; immunotherapy agents, including CAR T-cell therapies and checkpoint inhibitors, are reshaping durable response expectations with checkpoint inhibitors subdivided into CTLA-4 and PD-1/PD-L1 inhibitors; and targeted therapy agents, encompassing monoclonal antibodies and small molecule inhibitors, now demand precision patient selection with monoclonal antibodies studied across chimeric and humanized formats while small molecule inhibitors focus on cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors. This class-level segmentation underscores the need for tailored clinical development and commercial narratives.
When considering route of administration, injectable and oral modalities present distinct adherence, distribution, and administration challenges, with injectable forms requiring intramuscular, intravenous, or subcutaneous pathways that influence hospital and clinic workflows. Based on molecule type, biologics versus small molecules determine manufacturing complexity and regulatory pathways, where biologics include monoclonal antibodies and vaccines that carry cold-chain and scale considerations. Across indications such as blood cancer, breast, colorectal, lung, and prostate cancers, sub-segmentation in hematologic malignancies-leukemia and lymphoma-further refines strategic focus with leukemia divided into acute myeloid leukemia and chronic lymphocytic leukemia and lymphoma differentiated into Hodgkin and non-Hodgkin categories, each with unique clinical endpoints and care models. Finally, end users-hospitals, research institutes, and specialty clinics-and distribution channels-hospital pharmacies, online pharmacies, and retail pharmacies-shape access, reimbursement interactions, and provider engagement strategies. Taken together, this layered segmentation emphasizes that commercialization success requires synchronized clinical, medical affairs, and distribution planning tailored to each segment’s operational realities.
In-depth regional insights highlighting how distinct regulatory, reimbursement, and healthcare infrastructure dynamics across major global regions influence oncology therapy adoption
Regional dynamics vary substantially, influencing regulatory expectations, pricing frameworks, clinical trial landscapes, and treatment adoption curves. In the Americas, innovation hubs and large payer systems coexist with diverse regulatory pathways that incentivize rapid uptake of high-evidence therapies in specialty oncology centers while cost-containment pressures shape formulary negotiations and contracting sophistication. Across Europe, Middle East & Africa, heterogeneous health systems and reimbursement models require tailored value dossiers and country-specific access plans, with many national authorities emphasizing comparative effectiveness and budget impact analysis to guide adoption. In Asia-Pacific, dynamic growth in clinical trial capacity, rapid modernization of healthcare infrastructure, and evolving regulatory harmonization support accelerated introduction of novel agents, but market entry strategies must carefully account for localized pricing expectations and manufacturing localization opportunities.
Transitionally, these regional patterns suggest that companies should adopt differentiated market entry playbooks that align evidence generation, pricing strategy, and local partnerships with regional system characteristics. Effective regional planning balances global development efficiencies with local adaptation to ensure therapies achieve sustainable uptake and patient access across diverse health system architectures.
A granular assessment of competitive dynamics showing how established players, biotech innovators, and specialized service partners align capabilities to capture value in oncology therapeutics
Competitive positioning reflects a mix of established pharmas, emergent biotechnology innovators, and specialized contract developers that focus on niche modalities. Established companies leverage broad portfolios, deep payer relationships, and global commercial infrastructure to optimize launch sequencing and life-cycle management, while newer biotechnology firms concentrate on differentiated mechanisms of action, biomarker-driven indications, and strategic collaborations to accelerate clinical development. Contract development and manufacturing organizations, diagnostics partners, and specialized clinical operations providers play increasingly central roles in enabling scalable manufacturing and robust evidence generation.
Investor and partner activity continues to favor programs that combine strong translational rationale with feasible manufacturing and clear payer value propositions. Companies demonstrating the ability to integrate companion diagnostics, generate real-world evidence, and execute risk-sharing arrangements with payers gain access advantages. Moreover, cross-sector alliances-linking biotechs with specialty pharmacies, clinical networks, and technology providers-are becoming commonplace to ensure seamless patient identification, therapy delivery, and outcomes tracking. Taken together, these competitive dynamics favor organizations that align scientific differentiation with pragmatic commercialization and delivery capabilities.
Practical and prioritized recommendations for industry leaders to integrate translational science, manufacturing resilience, market access, and data strategies for durable commercial success
Industry leaders must prioritize integrated strategies that connect scientific differentiation to practical delivery, reimbursement, and scale. First, align translational development with value demonstration by embedding health economics and outcomes research early in clinical programs to produce robust evidence that resonates with payers and health systems. Second, invest in manufacturing flexibility and supply chain redundancy to mitigate tariff exposure and geopolitical risk while enabling rapid scale-up for biologics and cell therapies. Third, cultivate strategic partnerships across diagnostics, specialty pharmacies, and clinical networks to ensure efficient patient identification and adherence support, thereby maximizing real-world outcomes.
Additionally, adopt data-forward commercialization models that combine real-world evidence with adaptive trial designs and post-launch evidence generation to sustain reimbursement and justify premium pricing. Strengthen market access capabilities by preparing differentiated value dossiers at the country level and exploring outcomes-based contracting where appropriate. Finally, build cross-functional governance that aligns R&D, commercial, regulatory, and manufacturing decision-making to reduce time-to-launch and increase the probability of sustainable uptake. These actions, taken together, will enable organizations to convert scientific advances into durable commercial success while managing operational and policy headwinds.
A transparent and robust research methodology combining qualitative expert insights with secondary evidence and scenario analysis to underpin actionable conclusions for stakeholders
The research underpinning this analysis synthesizes primary and secondary inputs to ensure balanced, rigorous conclusions. Primary research incorporated interviews with clinical investigators, payer representatives, manufacturing and supply chain experts, and commercial leaders to validate strategic assumptions and operational constraints. Secondary research included peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public filings to triangulate factual details about therapeutic mechanisms, safety profiles, and clinical pathway evolution. These combined sources enabled a nuanced view of both technical feasibility and commercial applicability.
Methodologically, qualitative insights were mapped against observable operational trends to identify inflection points and risk factors. Where appropriate, scenario analysis was used to explore the implications of policy shifts and supply chain disruptions. The approach prioritized transparency in source attribution, methodological rigor in cross-validation, and practical framing for decision-makers. Limitations were acknowledged, including inherent uncertainty in future regulatory and reimbursement dynamics and variability across regional healthcare systems, which the methodology sought to mitigate through diverse stakeholder engagement and iterative validation.
A concise conclusion synthesizing how scientific advances, policy pressures, and strategic execution combine to determine oncology therapy adoption and long-term value
This executive summary synthesizes the critical dynamics that will shape oncology therapeutics in the near term: scientific innovation continues to expand therapeutic options, policy shifts and tariff changes compel operational adaptability, and fragmented regional systems demand customized access strategies. Strategic success will hinge on the ability to integrate translational science with manufacturing agility, evidence generation, and market access planning. Companies that operationalize cross-functional alignment, invest in localized manufacturing and supply resiliency, and build compelling value stories grounded in real-world outcomes will secure sustainable adoption.
In closing, the landscape rewards organizations that pair scientific differentiation with pragmatic delivery capabilities and proactive payer engagement. By doing so, stakeholders can translate clinical promise into measurable patient benefit and enduring commercial value, even as external pressures and rapid innovation continue to redefine what constitutes effective oncology care.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
181 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rapid adoption of personalized neoantigen vaccine platforms targeting tumor-specific mutations in solid cancers
- 5.2. Growing integration of ultra-sensitive liquid biopsy assays for minimal residual disease monitoring in hematologic malignancies
- 5.3. Expansion of CD19-targeted CAR T cell therapies into earlier lines of diffuse large B cell lymphoma treatment protocols
- 5.4. Emergence of next generation KRAS G12C and G12D inhibitors demonstrating durable responses across lung and colorectal cancers
- 5.5. Increasing partnerships between pharmaceutical companies and diagnostic developers for PD-L1 companion diagnostic co-development programs
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Oncology Drugs Market, by Drug Class
- 8.1. Chemotherapy Agents
- 8.1.1. Alkylating Agents
- 8.1.2. Antimetabolites
- 8.2. Hormonal Therapy Agents
- 8.3. Immunotherapy Agents
- 8.3.1. CAR T-Cell Therapy
- 8.3.2. Checkpoint Inhibitors
- 8.3.2.1. CTLA-4 Inhibitors
- 8.3.2.2. PD-1/PD-L1 Inhibitors
- 8.4. Targeted Therapy Agents
- 8.4.1. Monoclonal Antibodies
- 8.4.1.1. Chimeric
- 8.4.1.2. Humanized
- 8.4.2. Small Molecule Inhibitors
- 8.4.2.1. Cyclin-Dependent Kinase Inhibitors
- 8.4.2.2. Tyrosine Kinase Inhibitors
- 9. Oncology Drugs Market, by Route of Administration
- 9.1. Injectable
- 9.1.1. Intramuscular
- 9.1.2. Intravenous
- 9.1.3. Subcutaneous
- 9.2. Oral
- 10. Oncology Drugs Market, by Molecule Type
- 10.1. Biologics
- 10.1.1. Monoclonal Antibodies
- 10.1.2. Vaccines
- 10.2. Small Molecules
- 11. Oncology Drugs Market, by Indication
- 11.1. Blood Cancer
- 11.1.1. Leukemia
- 11.1.1.1. Acute Myeloid Leukemia
- 11.1.1.2. Chronic Lymphocytic Leukemia
- 11.1.2. Lymphoma
- 11.1.2.1. Hodgkin Lymphoma
- 11.1.2.2. Non-Hodgkin Lymphoma
- 11.2. Breast Cancer
- 11.3. Colorectal Cancer
- 11.4. Lung Cancer
- 11.5. Prostate Cancer
- 12. Oncology Drugs Market, by End User
- 12.1. Hospitals
- 12.2. Research Institutes
- 12.3. Specialty Clinics
- 13. Oncology Drugs Market, by Distribution Channel
- 13.1. Hospital Pharmacies
- 13.2. Online Pharmacies
- 13.3. Retail Pharmacies
- 14. Oncology Drugs Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Oncology Drugs Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Oncology Drugs Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. AbbVie Inc.
- 17.3.2. Agenus Inc.
- 17.3.3. Amgen Inc.
- 17.3.4. Après-demain SA
- 17.3.5. Aspen Pharmacare Holdings Limited
- 17.3.6. Astellas Pharma Inc.
- 17.3.7. AstraZeneca PLC
- 17.3.8. Bayer AG
- 17.3.9. BeiGene, Inc.
- 17.3.10. Bristol-Myers Squibb Company
- 17.3.11. C.H. Boehringer Sohn AG & Co. KG
- 17.3.12. Cipla Limited
- 17.3.13. Eli Lilly and Company
- 17.3.14. GSK plc
- 17.3.15. Johnson & Johnson Services, Inc.
- 17.3.16. Merck KGaA
- 17.3.17. Pfizer Inc.
- 17.3.18. Puma Biotechnology, Inc.
- 17.3.19. Roche Holding AG
- 17.3.20. Shorla Oncology
- 17.3.21. Sun Pharmaceutical Industries Ltd
- 17.3.22. Sutro Biopharma, Inc.
- 17.3.23. Takeda Pharmaceutical Company Limited
- 17.3.24. Viatris Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
